Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 6/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 5/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373898 | 0.81 | ATM (0.46) | CA2BACE1APPPSEN1PSEN2 | |
| SCHEMBL5373760 | 0.80 | ABCC3 (0.47) | CCR1CA2BACE1BCHEAPP | |
| SCHEMBL3804837 | 0.77 | EPHX1 (0.47) | CCR1BACE1APPPSEN1PSEN2 | |
| SCHEMBL3804839 | 0.77 | EPHX1 (0.47) | CCR1BACE1APPPSEN1PSEN2 | |
| SCHEMBL7789539 | 0.75 | CTRB1 (0.49) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7789551 | 0.75 | CTRB1 (0.49) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3797469 | 0.74 | CYP3A4 (0.48) | BACE1BCHEAPPPSEN1PSEN2 | |
| SCHEMBL3797474 | 0.74 | CYP3A4 (0.48) | BACE1BCHEAPPPSEN1PSEN2 | |
| SCHEMBL5364962 | 0.74 | CYP3A4 (0.46) | CCR1CA2BACE1CTSD | |
| SCHEMBL7387549 | 0.74 | SCN4A (0.46) | BACE1BCHEAPPPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279582-B2 | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2007-10-09 | — | — | US | disclosed |
| US-20030100755-A1 | Retroviral protease inhibiting compounds | ABBVIE INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1170289-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 2002-01-09 | — | — | EP | disclosed |
| US-5914332-A | NOVEL COMPOUNDS FOR USE AS HIV PROTEASE INHIBITORS IN TREATING HIV AND AIDS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100755-A1 | Retroviral protease inhibiting compounds | SERPINB1, PREP, TMPRSS15 | CCR1 1295/4885CA2 4302/4885BACE1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.